Log in to your Inderes Free account to see all free content on this page.
Novo Nordisk
236.90 DKK
+2.60 %
1,013 following
NOVO B
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Novo Nordisk
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 122,021.0 | 126,946.0 | 140,800.0 | 176,954.0 | 232,261.0 | 290,403.0 | 309,064.0 |
| growth-% | 4.0 % | 10.9 % | 25.7 % | 31.3 % | 25.0 % | 6.4 % | |
| EBITDA | 58,144.0 | 59,879.0 | 64,669.0 | 82,171.0 | 111,987.0 | 147,446.0 | 149,640.0 |
| EBIT | 52,483.0 | 54,126.0 | 58,644.0 | 74,809.0 | 102,574.0 | 128,339.0 | 127,658.0 |
| Profit before taxes | 48,553.0 | 53,130.0 | 59,080.0 | 69,062.0 | 104,674.0 | 127,191.0 | 130,540.0 |
| Net income | 38,951.0 | 42,138.0 | 47,757.0 | 55,525.0 | 83,683.0 | 100,988.0 | 102,434.0 |
| EPS | 8.20 | 9.03 | 10.39 | 12.26 | 18.67 | 22.67 | 23.06 |
| Dividend | 4.18 | 4.55 | 5.20 | 6.20 | 9.40 | 11.40 | 11.70 |
| Dividend ratio | 50.9 % | 50.4 % | 50.0 % | 50.6 % | 50.3 % | 50.3 % | 50.7 % |
Login required
This content is only available for logged in users
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | 47.7 % | 47.2 % | 45.9 % | 46.4 % | 48.2 % | 50.8 % | 48.4 % |
| EBIT-% | 43.0 % | 42.6 % | 41.7 % | 42.3 % | 44.2 % | 44.2 % | 41.3 % |
| ROE | 67.6 % | 66.5 % | 67.5 % | 66.5 % | 78.5 % | 70.4 % | 52.8 % |
| ROI | 31.0 % | 29.1 % | 24.6 % | 23.0 % | 26.6 % | 21.7 % | 18.9 % |
Login required
This content is only available for logged in users